Enrico Martin

65 Treatment and survival in the Netherlands References 1. Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res . 2013;33(6):2597-2604. 2. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg . 2009;249(6):1014-1022. doi:10.1097/ SLA.0b013e3181a77e9a 3. Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol . 2012;19(3):878-885. doi:10.1245/s10434-011-1978-7 4. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer . 2006;107(5):1065-1074. doi:10.1002/cncr.22098 5. Miao R, Wang H, Jacobson A , et al. Radiation -induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol . 2019;137:61-70. doi:10.1016/j.radonc.2019.03.015 6. Ferner RE, Lucas JD, O’Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18) FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg PS YCHI ATRY . 2000;68 (3):353 -357. doi:10.1136/jnnp.68.3.353 7. Broski SM, Johnson GB, Howe BM, et al. Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiol . 2016;45(8):1097-1105. doi:10.1007/ s00256-016-2394-7 8. Brooks JS, Freeman M, Enterline HT. Malignant “Triton” tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer . 1985;55(11):2543-2549. 9. Li G, Liu C, Liu Y, et al. Analysis of clinical features and prognosis of malignant triton tumor: A report of two cases and literature review. Oncol Lett . 2015;10(6):3551-3556. doi:10.3892/ol.2015.3762 10. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer . 2016;56:77-84. doi:10.1016/j.ejca.2015.12.015 11. Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol . 2014;4:324. doi:10.3389/fonc.2014.00324 12. Bradford D, Kim A. Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options Oncol . 2015;16(3):328. doi:10.1007/s11864-015- 0328-6 13. Davis A, O’Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol . 20 05;75 (1) :4 8 -53. doi:10.1016 / j. radonc.2004.12.020 14. Haas RL, Gronchi A, van de Sande MAJ, et al. Perioperative Management of Extremity Soft Tissue Sarcomas. J Clin Oncol . 2018;36(2):118-124. doi:10.1200/ JCO.2017.74.7527 3